Clinical Focus

Overview of TNBC

Current Treatment Landscape for TNBC

Early TNBC: Neoadjuvant and Adjuvant Therapies

Patient Case

Key Decision Point #1

Key Decision Point #2

Neoadjuvant Chemotherapy

Key Decision Point #2 (cont)

Key Decision Point #2 (cont)

Key Decision Point #3

pCR and Prognosis in the Adjuvant Setting

Back to the Patient Carboplatin -- To Add or Not to Add

Awaiting Data From the Ongoing NRG-BR003 Adjuvant Trial

Back to the Patient BRCA-Mutated TNBC

Adjuvant Platinum Therapy in Patients With BRCA-Positive Disease

Back to the Patient Residual Disease

Adjuvant Therapy for Residual Disease

CREATE-X DFS and OS Benefit for Capecitabine in TNBC

Challenges With Adjuvant Capecitabine

Ongoing Adjuvant Trials for Residual Disease

Metastatic TNBC

Approval of PARP Inhibitors for MBC

OlympIAD: Study Design

PARP Inhibition and Synthetic Lethality in Tumors With BRCA Mutations

OlympiAD: Olaparib Improves mPFS and ORR

OlympiAD Survival: Benefit Seen in First-Line Patients

OlympiAD: Safety and AEs

EMBRACA: Study Design

EMBRACA Primary Endpoint: PFS by Blinded Central Review

EMBRACA Interim OS Analysis

EMBRACA Safety: Selected AEs

MDACC Neoadjuvant Talazoparib Pilot Trial

Back to the Patient

IMpassion 130: Trial Design

IMpassion 130: PFS in ITT and PD-L1-Positive Subgroup

IMpassion 130: OS in ITT and PD-L1-Positive Subgroup

What About TNBC That is BRCA-Mutated and PD-L1-Positive?

Back to the Patient (cont)

EMBRACE Trial

Phase 3 Eribulin Study 301

Future Directions and Take-Home Points

IMMU-132: Sacituzumab Govitecan

AKT Inhibition

Take-Home Messages

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)